Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer

Journal of Clinical Oncology

Volumn 26, Issue 34, 2008, Pages 5553-5560

  Hassett, Michael J ^a   Hughes, Melissa E ^a   Niland, Joyce C ^a   Edge, Stephen B ^a   Theriault, Richard L ^a   Wong, Yu Ning ^a   Wilson, John ^a   Carter, W Bradford ^a   Blayney, Douglas W ^a   Weeks, Jane C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MEDICAL ONCOLOGY; MENOPAUSE; MIDDLE AGED; ODDS RATIO; RECEPTORS, ESTROGEN; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 57149118868     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.9705     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. American Cancer Society: Breast cancer facts & figures 2005-2006. http://www.cancer.org/downloads/STT/CAFF2005BrF.pdf
3. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682, 1997
4. Mansour EG, Gray R, Shatila AH, et al: Survival advantage of adjuvant chemotherapy in high-risk nodenegative breast cancer: Ten-year analysis - An intergroup study. J Clin Oncol 16:3486-3492, 1998
5. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
6. Fisher B, Jeong JH, Dignam J, et al: Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 30:62-66, 2001
7. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 30:5-15, 2001
8. Carlson RW, McCormick B: Update: NCCN breast cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 3:S7-S11, 2005 (suppl 1)
9. Carlson RW, Brown E, Burstein HJ, et al: NCCN Task Force report: Adjuvant therapy for breast cancer. J Natl Compr Canc Netw 4:S1-S26, 2006 (suppl 1)
10. National Comprehensive Cancer Network: Practice Guidelines in Oncology-Breast Cancer. Fort Washington, PA, National Comprehensive Cancer Network, 2002
11. International Breast Cancer Study Group: Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 94:1054-1065, 2002
12. Muss HB, Woolf S, Berry D, et al: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-1081, 2005
13. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
14. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569-1583, 2005
15. National Institutes of Health: Adjuvant therapy for breast cancer. NIH Consens Statement 17:1-35, 2000
16. Harlan LC, Abrams J, Warren JL, et al: Adjuvant therapy for breast cancer: Practice patterns of community physicians. J Clin Oncol 20:1809-1817, 2002
17. Mariotto A, Feuer EJ, Harlan LC, et al: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 94:1626-1634, 2002
18. Malin JL, Schuster MA, Kahn KA, et al: Quality of breast cancer care: What do we know? J Clin Oncol 20:4381-4393, 2002
19. Du XL, Key CR, Osborne C, et al: Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med 138:90-97, 2003
20. Palazzi M, De tomasi D, D'Affronto C, et al: Are international guidelines for the prescription of adjuvant treatment for early breast cancer followed in clinical practice? Results of a population-based study on 1547 patients. Tumori 88:503-506, 2002
21. Weeks JC: Outcomes assessment in the NCCN. Oncology (Williston Park) 11:137-140, 1997
22. Weeks J: Outcomes assessment in the NCCN: 1998 update - National Comprehensive Cancer Network. Oncology (Williston Park) 13:69-71, 1999
23. Niland JC: NCCN outcomes research database: Data collection via the Internet. Oncology (Williston Park) 14:100-103, 2000
24. Niland JC: NCCN Internet-based data system for the conduct of outcomes research. Oncology (Williston Park) 12:142-146, 1998
25. Edge SB, Niland JC, Bookman MA, et al: Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst 95:1514-1521, 2003
26. Christian CK, Niland J, Edge SB, et al: A multiinstitutional analysis of the socioeconomic determinants of breast reconstruction: A study of the National Comprehensive Cancer Network. Ann Surg 243:241-249, 2006
27. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
28. Katz JN, Chang LC, Sangha O, et al: Can comorbidity be measured by questionnaire rather than medical record review? Med Care 34:73-84, 1996
29. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer - Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19:3817-3827, 2001
30. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
31. Du X, Goodwin JS: Patterns of use of chemotherapy for breast cancer in older women: Findings from Medicare claims data. J Clin Oncol 19:1455-1461, 2001
32. Hébert-Croteau N, Brisson J, Latreille J, et al: Time trends in systemic adjuvant treatment for node-negative breast cancer. J Clin Oncol 17:1458-1464, 1999
33. Harlan LC, Clegg LX, Abrams J, et al: Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol 24:872-877, 2006
34. Hassett MJ, Hughes ME, Niland JC, et al: Selecting high priority quality measures for breast cancer quality improvement. Med Care 46:762-770, 2008
35. Fan C, Oh DS, Wessels L, et al: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560-569, 2006
36. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
37. Buyse M, Loi S, van't Veer L, et al: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183-1192, 2006
38. Sparano JA: TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347-350, 2006
39. Cardoso F, Van't Veer L, Rutgers E, et al: Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 26:729-735, 2008